1962- xylazine synthesized by Bayer in Germany, possible medicine for high blood pressure in humans
doi:10.1136/vr.85.19.512
Late 1960s - Whoops, too sedating for humans in clinical trials. But wait, how about as a veterinary anesthetic?
1970s - Gains popularity in veterinary circles for large animal procedures, often used in combination with other immobilizing drugs π΄π¦πππ
mid 1970s - Concerns arise about xylazine's transient impact on depressing hemoglobin ... including in impalas (yes, impalas). But vet use continues
2006 - xylazine identified in several people who fatally overdosed in Philadelphia, suggesting expansion of xylazine in the drug supply
2019 - Philadelphia starts seeing xylazine in nearly one-third of people who fatally overdosed from heroin or fentanyl ncbi.nlm.nih.gov/pmc/articles/Pβ¦
During a global emergency, making clever use of existing resources is a fundamental human impulse. But, the cavalier repurposing of hydroxychloroquine, chloroquine, and azithromycin during the COVID-19 pandemic has consequences.
"Is silence better than getting it wrong?" when it comes to emerging medication safety issues for patients - Priya Bahri asks of #drugsafety at #ICPE20
It's been 10 years since #OxyContin was re-engineered to make it hard to crush. But #publichealth benefits are still unclear. Here is a brief video of the epidemiology challenges.
A *product-centric* worldview, holds that abuse deterrence is primarily the property of the drug, and that that is the PRIMARY thing that changed with the reformulation, especially in the immediate aftermath.
A *person-centric* view holds that abuse deterrence is not merely a property of the drug, but rather an interaction between engineering and society, between physiochemical properties and point-of-prescribing medical decisions.